Project Grant R37CA286477

Award Date 6/6/24
Completion Date 5/31/29
Dollars Obligated $1.6M
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Cold Spring Harbor, NY 11724, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $686,979 to The Regents of the University of California, San Francisco (UCSF) to conduct research on disrupting tumor metabolism and enhancing anti-tumor immunity in diffuse midline gliomas (DMGs), a highly aggressive form of pediatric brain cancer. The key objectives are to: 1) delineate how the H3K27M mutation in DMGs upregulates glycolytic and citrate...
This Project Grant award from the National Institute on Aging (CFDA 93.866, Aging Research) provides $1,489,256 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the effects of a ketogenic diet on brain energy metabolism in aging and Alzheimer's disease. The key products and services to be delivered under this award include: 1) Developing advanced magnetic resonance spectroscopy techniques to measure biomarkers of brain energy metabolism, including...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop metabolic therapy and imaging for diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The research aims to identify and target the vulnerabilities induced by the H3K27M mutation that drives DMGs, specifically inhibiting the enzymes...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) provides funding to Northwestern University to study the underlying mechanisms by which certain types of cancers induce systemic changes in the vasculature and lymphatic system that contribute to the development of cancer cachexia. The $502,563 award, which runs from July 2024 to June 2029, supports a two-pronged research approach. The first focus is to further elucidate the molecular...
This $432,889 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to advance molecular imaging and metabolic therapies for reversing cachexia induced by pancreatic ductal adenocarcinoma (PDAC). The research team at The Johns Hopkins University will focus on disrupting glutamine metabolism in PDAC models, studying the effects on tumor and organ metabolism, as well as changes in the tumor and spleen immune...
This federal Project Grant award of $531,379, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The primary goals of this 5-year study are to: 1) Investigate baseline mitochondrial network architecture as a critical factor influencing NSCLC response to ADCs with the DXD...
This $523,480 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program supports research to understand and overcome resistance to KRAS inhibitor therapies in pancreatic ductal adenocarcinoma (PDAC). The Dana-Farber Cancer Institute, Inc. (DFCI) will lead this 5-year project to define how dysregulated iron metabolism and autophagy mechanisms contribute to both acute and long-term resistance to KRAS inhibitors in PDAC. The research aims...
The National Cancer Institute awarded a 5-year, $655,306 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) to develop a novel therapeutic strategy for treating isocitrate dehydrogenase (IDH)-mutant gliomas, a deadly form of brain cancer. The project aims to leverage the vulnerability of IDH-mutant gliomas to reactive metabolite accumulation by combining a potent glyoxalase 1 (GLO1) inhibitor with radiation therapy. The...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The goal is to evaluate whether a prebiotic-enriched diet can enhance the gut microbiome and improve response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma. The 5-year study will investigate the...
This federal Project Grant award for $2,636,509.00, awarded by the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants, supports a research study on the use of a ketogenic diet to target metabolism and normalize persistent eating disorder psychopathology in individuals who have recovered from anorexia nervosa (AN). The study has two phases - the R61 phase will establish biological targets as diet-related metabolic markers for AN and evaluate the safety,...

MECHANISM BY WHICH KETOGENIC DIET UNCOUPLES TUMOR GROWTH AND OVERALL SURVIVAL - THE OVERARCHING GOAL OF THIS PROPOSAL IS TO ADD TO THE UNDERSTANDING OF THE COMPLEX INTERACTION BETWEEN THE TUMOR AND THE HOST ORGANISM TO FACILITATE NEW THERAPEUTIC APPROACHES IN CANCER MEDICINE. SPECIFICALLY, WE AIM TO ESTABLISH THE MECHANISTIC EXPLANATION FOR THE OBSERVATION IN TWO IL-6 ASSOCIATED MURINE MODELS OF CANCER CACHEXIA THAT KD DELAYS TUMOR GROWTH BUT ACCELERATES CANCER CACHEXIA AND SHORTENS SURVIVAL. WE DISCOVERED THAT THIS UNCOUPLING MAY BE A CONSEQUENCE OF THE BIOCHEMICAL INTERACTION OF TWO SIMULTANEOUSLY OCCURRING NADPH-DEPENDENT PATHWAYS. WITHIN THE TUMOR, INCREASED PRODUCTION OF LPPS AND, CONSEQUENTLY, SATURATION OF THE GLUTATHIONE SYSTEM LEADS TO FERROPTOTIC DEATH OF CANCER CELLS. SYSTEMICALLY, REDOX IMBALANCE AND NADPH DEPLETION IMPAIRS THE BIOSYNTHESIS OF CORTICOSTERONE, THE MAIN REGULATOR OF METABOLIC STRESS, IN THE ADRENAL GLANDS. THE PROPOSAL SEEKS TO BUILD ON THESE DISCOVERIES IN THREE WAYS. FIRST, WE WILL DETERMINE SPECIFIC POLYUNSATURATED FAT ENRICHED DIETS AND FERROPTOSIS INDUCING DRUGS, INCLUDING LICENSED MEDICATIONS, THAT EXACERBATE THE ANTI-CANCER EFFECT. SECOND, AFTER VALIDATING THAT GLUCOCORTICOID DEFICIENCY IS A CRITICAL COMPONENT OF SURVIVAL REDUCTION OF THE HOST ORGANISM, USING PLASMA, LIVER, AND ADRENAL FOCUSED ASSAYS, WE WILL USE SYSTEMATIC PHARMACOLOGICAL RESCUE EXPERIMENTS TO ENABLE A THERAPEUTIC WINDOW FOR KD INTERVENTION. THIRD, WE WILL TRACK HOW OXIDATIVE STRESS INDUCED GDF-15 ELEVATIONS MAY CONSPIRE WITH IL-6 ELEVATIONS TO DRIVE CACHEXIA ASSOCIATED ANOREXIA VIA NEURONAL CIRCUITS AND THEREBY CAUSE THE NEGATIVE ENERGY BALANCE THAT ACCELERATES CACHEXIA ONSET IN KD FED MICE. THE RESULTS OF THIS RESEARCH MAY BE OF INTEREST TO SCIENTISTS AND MEDICAL PROFESSIONALS. A COMBINATION OF ADMINISTRATION OF SYNTHETIC GCS MAY IMPROVE FOOD INTAKE, NORMALIZES GLUCOSE HOMEOSTASIS AND UTILIZATION OF NUTRITIONAL SUBSTANCES, DELAY THE ONSET OF CANCER CACHEXIA AND EXTENDS SURVIVAL OF TUMOR-BEARING MICE FED KD, WHILE NOT COUNTERACTING THE REDUCED TUMOR GROWTH INDUCED BY THE KD-INDUCED FERROPTOSIS. THESE STUDIES WILL EMPHASIZE THE IMPORTANCE OF CONSIDERING THE IMPACT OF CANCER TREATMENTS ON THE HOST AND THE TUMOR.

Posted 6/6/24, 12:00 AM